Gennaro Musella

Dr. Gennaro Musella

orcid
DDS, MSc, PhD Cand, Lecturer

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
BABhawna Agarwal
Bhawna Agarwal
Maria Eleonora BizzocaMaria Eleonora Bizzoca
Maria Eleonora Bizzoca
Gennaro MusellaGennaro Musella
Gennaro Musella
DANILA DE VITODANILA DE VITO
DANILA DE VITO
Lorenzo Lo MuzioLorenzo Lo Muzio
Lorenzo Lo Muzio
Flavio PisaniFlavio Pisani
Flavio Pisani
Background: Periodontal disease and tooth loss have been long suggested as risk factors of mild cognitive impairment. The underlying mechanisms could be systemic chronic inflammatory mediators, direct pathologic challenge to the nervous system, malnutrition and/or loss of neurosensory stimulation input causing brain atrophy. This review aimed to examine the existing literature studies linking the effect of periodontal disease and tooth loss on the development of mild cognitive impairment. Methods: A systematic review using PEO was conducted. Three electronic databases, namely Embase, Medline and DOSS (UCLan), were searched for relevant articles published up to April 2023. Google Scholar and a hand search were also conducted to ensure no relevant studies had been missed. The Newcastle–Ottawa scale was used to assess the quality of studies. Results: The findings showed that chronic periodontitis and tooth loss, both individually and in combination, led to an increased risk of mild cognitive decline in adults over 50 years. Within the limitations of this review, periodontitis and tooth loss both contribute to an increased risk of mild cognitive impairment and dementia, but the evidence so far is not strong. Conclusions: In future, more robustly designed studies investigating periodontal disease and tooth losslink with cognitive health decline are required with a longer follow-up duration.

27 January 2025 in Journal of Oral Rehabilitation
Verified
Journal Article
Open access
Gennaro MusellaGennaro Musella
Gennaro Musella
Federica CanforaFederica Canfora
Federica Canfora
VCVITO CARLO ALBERTO CAPONIO
VITO CARLO ALBERTO CAPONIO
EVEmmanouil Vardas
Emmanouil Vardas
MKMaria Kouri
Maria Kouri
DADaniela Adamo
Daniela Adamo
Background: According to the ICOP 2020, Burning Mouth Syndrome (BMS) is a chronic orofacial pain disorder characterised by an intraoral burning sensation, which represents the main diagnostic criterion. However, some patients experience other symptoms such as xerostomia, taste alterations, and globus, without the burning sensation (non‐BMS).Objective: This study aims to explore non‐BMS as a distinct subclinical entity by comparing the classical BMS with this new group of patients in a case–control study, addressing gaps in current diagnostic criteria.Methods: Eighty‐three non‐BMS patients were compared with an equal number of BMS patients matched for age and sex. Data on sociodemographic and risk factors, systemic comorbidities and drug intake, symptom patterns, psychological profiles were collected and statistically analysed.Results: No significant differences between BMS and non‐BMS groups were found in sociodemographic characteristics, comorbidities, drug consumption and extraoral symptoms. Both groups reported similar symptoms patterns, with discomfort intensifying in the evening. Although oral symptoms prevalence varied, with the burning sensation exclusive to BMS patients, none of these differences reached statistical significance. Psychological assessments revealed mild depression (17 [14–19] vs. 17 [14–20], p 0.981), mild to moderate anxiety (18 [15–21] vs. 17 [15–20.5], p = 0.767), and sleep disturbance (5 [4–7] vs. 8 [5–10], p < 0.001) in both groups.Conclusion: Non‐BMS patients exhibit similarities to BMS patients yet remain unclassified under current diagnostic criteria. Therefore, we have suggested the term “Oral Dysaesthetic and Perceptual Disorder (ODPD)” to define these patients (non‐BMS). This study emphasises the need to expand diagnostic criteria to better identify and manage ODPD patients.

14 December 2024 in Journal of Dentistry
Verified
Journal Article
Open access
VCVITO CARLO ALBERTO CAPONIO
VITO CARLO ALBERTO CAPONIO
ASAjay Sharma
Ajay Sharma
Gennaro MusellaGennaro Musella
Gennaro Musella
Vittoria PerrottiVittoria Perrotti
Vittoria Perrotti
AQAlessandro Quaranta
Alessandro Quaranta
Dental implant treatment can still fail due to various factors. The aim of this retrospective cohort study was to assess the influence of operator experience in a postgraduate educational setting, as well as patient, implant, and surgical risk factors on the incidence of the dental implant failure. The dental records of 1049 implants with a mean follow-up of 794.70 days were analysed. Variables included operator experience (year of specialty study) and clinic-pathological patients' related variables. Clinic-pathological associations were explored and a Cox regression model accounted for implant survival factors. Multivariate analysis revealed that a history of periodontitis and smoking were the only factors with independent prognostic value, with hazard ratios of 2.0 (95 % CI: 1.0-4.0, p = 0.048) and 1.9 (95 % CI: 1.0-3.6, p = 0.039) respectively. Conversely, despite implant treatment delivered by early career students had a higher failure rate (5.6 %) compared to advanced career students (3.7 %), this difference was statistically significant only in the univariate analysis. Periodontitis and smoking are independent prognostic variables, with career level potentially biasing complex case allocation to advanced students. Targeted educational interventions, including virtual reality and artificial intelligence, should be emphasized in student training. University-based implant trials must consider operator career stage. The study underscores the importance of operator experience in dental implant success. It highlights that while clinical experience influences outcomes, factors like a history of periodontitis and smoking are independent predictors of implant failure. These findings emphasize the need for targeted educational interventions to improve clinical training and patient outcomes.

24 November 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
MARIO DIOGUARDIMARIO DIOGUARDI
MARIO DIOGUARDI
SCStefania Cantore
Stefania Cantore
DSDiego Sovereto
Diego Sovereto
LSLorenzo Sanesi
Lorenzo Sanesi
AMAngelo Martella
Angelo Martella
ABAndrea Ballini
Andrea Ballini
Solenopsis invicta, a South American ant species from the Formicidae family (subfamily Myrmicinae), has recently established a stable settlement in Europe, raising public health concerns due to its venomous stings. The venom of S. invicta is rich in bioactive molecules, particularly piperidine alkaloids such as solenopsin A and peptides (Sol 1–4). These compounds have been implicated in various health applications, including antimicrobial, anti-inflammatory, and antitumour activities. While previous reviews have focused on the ecological and allergenic risks posed by S. invicta, this scoping review aims to evaluate the potential therapeutic uses of S. invicta venom by summarizing existing scientific evidence and providing a novel synthesis of recent research on its bioactive components. Furthermore, this study, by describing the unique biological aspects of S. invicta, provides an overview of its direct impact on public health, highlighting new findings on the venom’s role in inhibiting bacterial biofilm formation and modulating cancer growth pathways through gene regulation. A search of databases (PubMed, Scopus, Science Direct, and Cochrane Library) identified 12,340 articles, from which 11 studies met the eligibility criteria. These studies included seven microbiological investigations and four studies on tumour cell lines and animal models. The findings suggest that S. invicta venom could inhibit biofilm formation, combat fungal infections, and suppress tumour growth. However, further research, including clinical trials, is required to fully elucidate the safety and efficacy of these bioactive molecules in human medicine, for their potential use in drug discovery to counteract several diseases, including cancer.

24 March 2025 in Oral Diseases
Verified
Journal Article
Open access
Gennaro MusellaGennaro Musella
Gennaro Musella
MCMartina Coppini
Martina Coppini
FSFábio França Vieira e Silva
Fábio França Vieira e Silva
Giuseppina CampisiGiuseppina Campisi
Giuseppina Campisi
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
APAlejandro Ismael Lorenzo Pouso
Alejandro Ismael Lorenzo Pouso
Background: Tumor‐stroma ratio (TSR) has been recognized as a significant prognostic factor in various cancers. This systematic review evaluates the role of TSR in head and neck squamous cell carcinoma (HNSCC) and its association with patient outcomes such as overall survival (OS), disease‐free survival (DFS), disease‐specific survival (DSS), and lymph node metastasis (LNM).Methods: A comprehensive search was conducted across Scopus, Embase, PubMed, and Web of Science. Nineteen studies were included. Data extraction and quality assessment were performed progressively, with meta‐analyses. All studies assessed TSR using hematoxylin and eosin staining of tissue samples. The meta‐analyses focused on the impact of TSR on OS, DFS, DSS, and LNM, providing pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding confidence intervals (CIs).Results: Meta‐analysis revealed a significant association between TSR and OS (HR 1.99, 95% CI 1.71–2.32, p < 0.001), DFS (HR 2.07, 95% CI 1.80–2.39, p < 0.001), DSS (HR 2.33, 95% CI 1.95–2.78, p < 0.001), and LNM (OR 1.76, 95% CI 1.15–2.70, p = 0.01). Minimal to low heterogeneity was detected among studies, and no publication bias was observed.Conclusions: TSR can effectively identify high‐risk patients, being a reliable prognostic marker that could be readily integrated into routine pathology practice for HNSCC.

Verified
Journal Article
Open access
PDF file
MARIO DIOGUARDIMARIO DIOGUARDI
MARIO DIOGUARDI
Gennaro MusellaGennaro Musella
Gennaro Musella
Maria Eleonora BizzocaMaria Eleonora Bizzoca
Maria Eleonora Bizzoca
DSDiego Sovereto
Diego Sovereto
CGCiro Guerra
Ciro Guerra
ABAndrea Ballini
Andrea Ballini
Head and Neck Squamous Cell Carcinoma (HNSCC) is a heterogeneous group of malignancies with poor survival outcomes, particularly in advanced stages. Identifying prognostic biomarkers could help improve patient management. miR-375, a small non-coding RNA, has been shown to influence tumor growth and immune responses, making it a candidate biomarker. This study aims to evaluate the role of miR-375 expression in predicting survival outcomes in HNSCC patients. A systematic review and meta-analysis were conducted according to PRISMA guidelines, incorporating data from six studies and the TGCA cohort, encompassing 452 patients. Fixed-effects models were applied to calculate aggregated hazard ratios (HRs) for overall survival (OS). Kaplan–Meier curves were analyzed using the Tierney method, and Trial Sequential Analysis (TSA) was performed to assess statistical power. Low miR-375 expression was associated with poorer OS, with an aggregated HR of 1.23 (95% CI: 1.10–1.37). Subgroup analysis showed consistent trends across oral and laryngeal squamous cell carcinoma. Sensitivity analysis confirmed these findings. TSA revealed that although the number of patients was sufficient, statistical power was insufficient to confirm a predefined risk reduction ratio (RRR) of 49%. Data from the TGCA cohort supported the meta-analysis findings, with an HR for OS of 1.32 (95% CI: 0.96–1.8). Low miR-375 expression is associated with worse survival outcomes in HNSCC patients, indicating its potential as a prognostic biomarker and therapeutic target. However, the retrospective nature of the included studies underscores the need for prospective research to validate these findings.